Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCL017
MIFTS: 59

B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for B-Cell Lymphoma

About this section

MalaCards integrated aliases for B-Cell Lymphoma:

Name: B-Cell Lymphoma 12 20 29 15 37
Lymphoma, B-Cell 20 44 39
B-Cell Lymphomas 74 15
B-Cell Lymphocytic Neoplasm 12
Lymphoma B-Cell 54

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:707
MeSH 44 D016393
NCIt 50 C3457
SNOMED-CT 67 109979007
ICD10 32 C85.1
UMLS 71 C0079731
Sources

Summaries for B-Cell Lymphoma

About this section
GARD : 20 B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders. Treatment is based on many factors, including the severity of the condition and the associated signs and symptoms.

MalaCards based summary : B-Cell Lymphoma, also known as lymphoma, b-cell, is related to diffuse large b-cell lymphoma and marginal zone b-cell lymphoma. An important gene associated with B-Cell Lymphoma is MIR17 (MicroRNA 17), and among its related pathways/superpathways are Prolactin Signaling Pathway and MicroRNAs in cancer. The drugs Epirubicin and Neuroprotective Agents have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and b cells, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in B cells.

Wikipedia : 74 Lymphoma is a group of blood malignancies that develop from lymphocytes (a type of white blood cell).... more...

Sources

Related Diseases for B-Cell Lymphoma

About this section

Diseases in the B-Cell Lymphoma family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1287)
# Related Disease Score Top Affiliating Genes
1 diffuse large b-cell lymphoma 33.8 REL PRDM1 PASD1 MYC MIR17 MALT1
2 marginal zone b-cell lymphoma 33.7 MALT1 IRF4 CCND1 BCL6 BCL2 BCL10
3 lymphoma, mucosa-associated lymphoid type 33.7 REL MYC MALT1 IRF4 CCND1 BCL6
4 primary mediastinal b-cell lymphoma 33.5 REL BCL6 BCL2 BCL11A
5 primary mediastinal large b-cell lymphoma 33.2 IRF4 BCL6
6 follicular lymphoma 33.2 MYC IRF4 CCND1 BCL6 BCL2 BCL10
7 plasmablastic lymphoma 33.2 PRDM1 MYC BCL6
8 primary cutaneous marginal zone b-cell lymphoma 33.2 MALT1 IRF4 BCL10
9 nodal marginal zone b-cell lymphoma 33.1 MALT1 BCL6 BCL2
10 lymphoma 33.1 REL PVT1 PRDM1 PASD1 MYC MALT1
11 intravascular large b-cell lymphoma 33.1 BCL6 BCL2
12 primary cutaneous diffuse large b-cell lymphoma, leg type 33.1 MYC IRF4
13 diffuse large b-cell lymphoma of the central nervous system 32.9 MYC BCL2
14 reticulosarcoma 32.8 MYC BCL6 BCL2
15 primary cutaneous b-cell lymphoma 32.8 PRDM1 BCL6
16 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 32.7 MYC BCL6 BCL2
17 primary central nervous system lymphoma 32.7 BCL6 BCL2
18 monoclonal gammopathy of uncertain significance 32.6 MYC IRF4 CCND1
19 richter's syndrome 32.6 MYC MIR17 IRF4
20 burkitt lymphoma 32.4 TP53COR1 PVT1 PRDM1 MYC IRF4 BCL6
21 central nervous system lymphoma 32.2 PRDM1 MYC MALT1 BCL6
22 lymphoma, non-hodgkin, familial 32.0 MYC MIR20A MIR17 MALT1 IRF4 CCND1
23 lymphoma, hodgkin, classic 32.0 REL PVT1 MIR20A IRF4 BCL6 BCL2
24 gastric lymphoma 31.9 MIR17 IRF4 BCL6 BCL2 BCL10
25 nodular lymphocyte predominant hodgkin lymphoma 31.9 CCND1 BCL6
26 lymphosarcoma 31.9 BCL6 BCL2
27 chromosomal triplication 31.9 MALT1 BCL3
28 lymphoma aids related 31.8 MYC BCL6
29 mantle cell lymphoma 31.8 PRDM1 MYC MIR17 MALT1 MALAT1 GAS5
30 leukemia 31.8 MYC HOTAIR GAS5 CCND1 BCL3 BCL11A
31 leukemia, acute lymphoblastic 31.7 MYC MIR17 IRF4 BCL6 BCL2
32 lung lymphoma 31.7 MALT1 BCL6
33 bone lymphoma 31.6 IRF4 BCL6
34 plasmacytoma 31.6 PVT1 PRDM1 MYC IRF4 CCND1
35 breast lymphoma 31.5 IRF4 BCL6
36 gastrointestinal lymphoma 31.5 MALT1 CCND1 BCL6
37 t-cell lymphoblastic leukemia/lymphoma 31.5 REL MYC IRF4 GAS5 CCND1 BCL2
38 gallbladder lymphoma 31.4 MALT1 IRF4 CCND1 BCL6
39 adult lymphoma 31.4 MYC IRF4 BCL6
40 human herpesvirus 8 31.4 BCL6 BCL2
41 mature t-cell and nk-cell lymphoma 31.3 MYC MIR17 BCL6
42 orbit lymphoma 31.3 MALT1 BCL10
43 extramedullary plasmacytoma 31.2 IRF4 CCND1 BCL2
44 mature b-cell neoplasm 31.1 PVT1 PRDM1 MYC MIR17 IRF4 CCND1
45 leukemia, chronic lymphocytic 31.1 TP53COR1 REL MYC MIR20A MIR17 IRF4
46 pediatric lymphoma 31.1 MYC IRF4 BCL6
47 in situ carcinoma 31.0 MYC MIR17 CCND1
48 leukemia, acute myeloid 31.0 TUG1 MYC MIR17 MALAT1 HOTAIR CCND1
49 inflammatory myofibroblastic tumor 31.0 MYC CCND1 BCL2
50 leukemia, chronic lymphocytic 2 30.9 BCL3 BCL2

Graphical network of the top 20 diseases related to B-Cell Lymphoma:



Diseases related to B-Cell Lymphoma
Sources

Symptoms & Phenotypes for B-Cell Lymphoma

About this section

MGI Mouse Phenotypes related to B-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 BCL10 BCL11A BCL2 BCL3 BCL6 CCND1
2 immune system MP:0005387 9.36 BCL10 BCL11A BCL2 BCL3 BCL6 CCND1
Sources

Drugs & Therapeutics for B-Cell Lymphoma

About this section

Drugs for B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2 Neuroprotective Agents Phase 4
3 Mitogens Phase 4
4
Apatinib Phase 4 811803-05-1
5 Endothelial Growth Factors Phase 4
6
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
7
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Blinatumomab Approved, Investigational Phase 2, Phase 3 853426-35-4
10
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
11
Chlorambucil Approved Phase 3 305-03-3 2708
12
Vinblastine Approved Phase 3 865-21-4 13342 241903
13
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
14
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
17
Idarubicin Approved Phase 3 58957-92-9 42890
18
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
19
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
20
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
21
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
22
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
23
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
24
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
25
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
26
Gemcitabine Approved Phase 3 95058-81-4 60750
27
ofatumumab Approved Phase 3 679818-59-8 6918251
28
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
29
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
30
Bevacizumab Approved, Investigational Phase 3 216974-75-3
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
32
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
33
Tenofovir Experimental, Investigational Phase 3 147127-20-6 464205
34 Iodine-131 anti-B1 antibody Phase 3
35 Epoetin alfa Phase 3 113427-24-0
36 Anti-HIV Agents Phase 3
37 Anti-Retroviral Agents Phase 3
38 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
39 Hematinics Phase 2, Phase 3
40 Antidotes Phase 2, Phase 3
41 Calcium, Dietary Phase 3
42 Reverse Transcriptase Inhibitors Phase 3
43 Gastrointestinal Agents Phase 3
44 Antiemetics Phase 3
45 Hydrocortisone 17-butyrate 21-propionate Phase 3
46 Hydrocortisone hemisuccinate Phase 3
47 Folic Acid Antagonists Phase 3
48 Calciferol Phase 3
49 Vaccines Phase 3
50 Immunoglobulin Idiotypes Phase 3

Interventional clinical trials:

(show top 50) (show all 1425)
# Name Status NCT ID Phase Drugs
1 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Unknown status NCT03579082 Phase 4 Decitabine
2 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
3 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
4 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
5 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
6 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
7 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Recruiting NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
8 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
9 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
10 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial Not yet recruiting NCT02992834 Phase 4
11 Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions Unknown status NCT02867553 Phase 3 rituximab
12 Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma Unknown status NCT02767674 Phase 3 Rituximab;Gemcitabine;Oxaliplatin;Cyclophosphamide;Epirubicin Injectable Product;Vindesine;Prednisone
13 Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study Unknown status NCT02777736 Phase 3 Methotrexate
14 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
15 CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma Unknown status NCT03391726 Phase 2, Phase 3
16 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
17 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
18 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
19 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
20 An Randomized, Open-label, Phase III Study Comparing Thalidomide Combined With R-CHOP and R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients Unknown status NCT03318835 Phase 3 Thalidomide combined with R-CHOP;R-CHOP
21 Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03229616 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
22 Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study Unknown status NCT02428751 Phase 3 Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
23 A Phase â…¢, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients Unknown status NCT02772822 Phase 3 SCT400 plus CHOP;Rituximab plus CHOP
24 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
25 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
26 A Multicenter,Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH and R-CEOP90, With or Without Upfront Auto-HSCT，in Newly Diagnosed Young Patients With Intermediate/High-risk DLBCL Unknown status NCT03213977 Phase 3 R-DA-EPOCH;R-DA-EPOCH + auto-HSCT;R-CEOP90;R-CEOP90 + auto-HSCT
27 A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
28 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
29 Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma Unknown status NCT03018626 Phase 3 Rituximab;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide;Prednisone;Doxorubicin;Cyclophosphamide;Vindesine;Bleomycin
30 A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed NCT01197560 Phase 2, Phase 3 Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide
31 Rituximab + Standard CHOP (Rï½¥S-CHOP) vs Rituximab+ Bi-weekly CHOP (Rï½¥Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
32 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
33 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Completed NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
34 A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
35 Treatment of Mature B-cell Lymphoma/Leukaemia A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study Completed NCT00162656 Phase 3 half cyclophosphamide;without COPADM3;mini CYVE, without 3 maintenance courses;LMB B;LMB C
36 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
37 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
38 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Completed NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
39 A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line Completed NCT02268045 Phase 3
40 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
41 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
42 Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Etoposide;Cytarabine;Melphalan
43 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
44 Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
45 Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma. Completed NCT00144755 Phase 3 Darbepoetin alfa
46 Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1. Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
47 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01014208 Phase 3 OFATUMUMAB + DHAP;RITUXIMAB + DHAP
48 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed NCT01855750 Phase 3 Ibrutinib;Placebo;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone (or equivalent)
49 A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01148446 Phase 3 Cyclophosphamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
50 Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) Completed NCT00210353 Phase 3 chlorambucil (drug);rituximab+chlorambucil;rituximab

Search NIH Clinical Center for B-Cell Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


ibritumomab tiuxetan
Ibrutinib
rituximab

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for B-Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to B-Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, b-cell

Sources

Genetic Tests for B-Cell Lymphoma

About this section

Genetic tests related to B-Cell Lymphoma:

# Genetic test Affiliating Genes
1 B-Cell Lymphoma 29
Sources

Anatomical Context for B-Cell Lymphoma

About this section

MalaCards organs/tissues related to B-Cell Lymphoma:

40
T Cells, Bone Marrow, B Cells, Thyroid, Myeloid, Colon, Prostate
Sources

Publications for B-Cell Lymphoma

About this section

Articles related to B-Cell Lymphoma:

(show top 50) (show all 29096)
# Title Authors PMID Year
1
MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. 47 61
18941111 2009
2
Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. 61 54
20442643 2010
3
Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. 61 54
20428773 2010
4
Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution. 54 61
20331331 2010
5
IRF4 expression without IRF4 rearrangement is a general feature of primary cutaneous diffuse large B-cell lymphoma, leg type. 54 61
20054341 2010
6
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. 61 54
20190733 2010
7
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. 61 54
20122924 2010
8
Xeroderma pigmentosum skin: an immune privilege site for tumor development. 54 61
19719835 2010
9
Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. 61 54
19714753 2010
10
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. 61 54
20371683 2010
11
The expression of Bcl-2 by proliferating cells varies in different categories of B-cell lymphoma. 61 54
20459572 2010
12
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. 54 61
20371444 2010
13
Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. 54 61
20303013 2010
14
Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. 54 61
19889619 2010
15
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 54 61
19965662 2010
16
An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. 54 61
20490333 2010
17
Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b. 61 54
19966860 2010
18
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 61 54
20062012 2010
19
Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. 54 61
18815567 2010
20
CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation. 61 54
20093404 2010
21
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. 54 61
20081860 2010
22
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. 54 61
20004001 2010
23
Mechanisms of chromosomal rearrangement in the human genome. 54 61
20158866 2010
24
Deregulation of H3K27 methylation in cancer. 54 61
20104248 2010
25
Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes. 54 61
20174727 2010
26
Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. 61 54
20093241 2010
27
Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. 54 61
20107311 2010
28
Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma. 54 61
20130454 2010
29
Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. 61 54
20103729 2010
30
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 61 54
20054396 2010
31
Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. 61 54
19857547 2010
32
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. 54 61
19965678 2010
33
[Correlation of Bcl-2 with immunological subtype and prognosis in diffuse large B-cell lymphoma.]. 61 54
20302777 2010
34
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. 61 54
19797725 2010
35
REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. 61 54
19289490 2009
36
Long-range oncogenic activation of Igh-c-myc translocations by the Igh 3' regulatory region. 61 54
20010689 2009
37
Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. 54 61
20016842 2009
38
Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? 61 54
19860620 2009
39
[Construction of expression plasmid for fused idiotypic DNA vaccine of B-cell lymphoma]. 61 54
20030925 2009
40
Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells. 54 61
20032398 2009
41
Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. 54 61
19734449 2009
42
[Clinicopathologic and immunohistochemical study of intra-abdominal non-Hodgkin B-cell lymphoma occurring in children]. 61 54
20079016 2009
43
[Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. 54 61
20079013 2009
44
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. 54 61
19775297 2009
45
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. 61 54
19897720 2009
46
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. 54 61
19814686 2009
47
Gene expression profiling of diffuse large B-cell lymphoma -- comparison depending on the CD21 antigen expression. 61 54
20009432 2009
48
Analysis of CXCL9 and CXCR3 expression in a case of intravascular large B-cell lymphoma. 54 61
19766346 2009
49
Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells. 61 54
19725825 2009
50
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. 54 61
19917125 2009
Sources

Variations for B-Cell Lymphoma

About this section
Sources

Expression for B-Cell Lymphoma

About this section
Search GEO for disease gene expression data for B-Cell Lymphoma.
Sources

Pathways for B-Cell Lymphoma

About this section

Pathways related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Prolactin Signaling Pathway 1 36
Show member pathways
 12.31 REL MYC CCND1 BCL2
2
MicroRNAs in cancer 36
12.29 MYC MIR20A MIR17 CCND1 BCL2
3
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.15 REL MALT1 BCL6 BCL3 BCL10
4
NF-kappaB Signaling 4
12.15 REL PRDM1 MALT1 IRF4 BCL6 BCL10
5
Apoptosis and Autophagy 4
12.06 MYC MALT1 BCL2 BCL10
6
DNA Damage Response 1
Show member pathways
 12.03 MYC MIR20A MIR17 CCND1 BCL2
7
C-type lectin receptor signaling pathway 36
Show member pathways
 12.02 REL MALT1 BCL3 BCL10
8
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 11.83 REL MYC MALT1 IRF4 BCL6 BCL10
9
NF-kappa B signaling pathway 36
11.76 MALT1 BCL2 BCL10
10
DNA Damage Response (only ATM dependent) 1
11.73 MYC CCND1 BCL6 BCL2
11
Small cell lung cancer 36
11.68 MYC CCND1 BCL2
12
C-MYB transcription factor network 1
11.59 MYC CCND1 BCL2
13
Validated targets of C-MYC transcriptional repression 1
11.47 MYC CCND1 BCL2
14
Photodynamic therapy-induced AP-1 survival signaling. 1
11.34 CCND1 BCL3 BCL2
15
DNA damage_ATM/ATR regulation of G1/S checkpoint 23
11.25 REL MYC CCND1
16
Interleukin-4 and 13 signaling 65
11.08 MYC IRF4 CCND1 BCL6 BCL2
17
Atypical NF-kappaB pathway 1
10.69 REL BCL3
Sources

GO Terms for B-Cell Lymphoma

About this section

Cellular components related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CBM complex GO:0032449 8.96 MALT1 BCL10
2 polkadots GO:0002096 8.62 MALT1 BCL10

Biological processes related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.92 MYC MALT1 BCL6 BCL3 BCL2
2 cellular response to DNA damage stimulus GO:0006974 9.91 MYC CCND1 BCL6 BCL3 BCL2
3 negative regulation of gene expression GO:0010629 9.85 REL PRDM1 MIR20A MIR17
4 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.63 REL BCL3 BCL10
5 cellular response to lipopolysaccharide GO:0071222 9.62 MIR20A MIR17 MALT1 BCL10
6 negative regulation of toll-like receptor signaling pathway GO:0034122 9.54 MIR17 IRF4
7 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.54 MYC MALT1 BCL10
8 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.49 MIR20A MIR17
9 germinal center formation GO:0002467 9.48 BCL6 BCL3
10 cellular response to hypoxia GO:0071456 9.46 MYC MIR17 MALAT1 BCL2
11 regulation of T cell receptor signaling pathway GO:0050856 9.43 MALT1 BCL10
12 response to fungus GO:0009620 9.4 MALT1 BCL10
13 cytokine-mediated signaling pathway GO:0019221 9.35 MYC IRF4 CCND1 BCL6 BCL2
14 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.26 MIR20A MIR17
15 regulation of apoptotic process GO:0042981 9.02 MALT1 BCL6 BCL3 BCL2 BCL10

Molecular functions related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.76 REL PRDM1 PASD1 MYC IRF4 BCL6
2 sequence-specific DNA binding GO:0043565 9.72 REL PRDM1 IRF4 BCL6 BCL2
3 protease binding GO:0002020 9.54 MALT1 BCL2 BCL10
4 DNA-binding transcription factor activity GO:0003700 9.5 REL PRDM1 MYC IRF4 BCL6 BCL3
5 kinase activator activity GO:0019209 9.26 MALT1 BCL10
6 transcription factor binding GO:0008134 9.1 MYC IRF4 CCND1 BCL3 BCL2 BCL10
Sources

Sources for B-Cell Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....